title: Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute.
abstract: We report the results of unrelated cord blood transplantation (UCBT) for patients with adult T-cell leukemia/lymphoma (ATLL) conducted in our single institute. Ten patients with ATLL (nine acute and one lymphoma-type) received UCBT during the period from August 2003 to July 2011. The median age at the time of diagnosis of ATLL was 51 years (range 37-64). The median period from diagnosis of ATLL to UCBT was 130 days (range 94-344). Conditioning regimens were myeloablative for six and reduced intensity for four. The median number of infused nucleated cells and CD34 positive cells were 2.52 × 10(7)/kg and 1.04 × 10(5)/kg, respectively. There was no engraftment failure. Three patients developed grade II acute graft versus host disease, and four developed grade III. The estimated 2-year overall survival was 40 % (95 % CI 12-67 %). Four of six chemosensitive patients prior to UCBT survived for 1035, 793, 712, and 531 days post-UCBT, respectively. There were no survivors among the four chemorefractory patients prior to UCBT. Our data indicates that UCBT is feasible and provides long-term survival in patients with chemosensitive ATLL.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Nakamura
authors.forename: Eijiro
authors.initials: E
authors.lastname: Oku
authors.forename: Kei
authors.initials: K
authors.lastname: Nomura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Morishige
authors.forename: Yuka
authors.initials: Y
authors.lastname: Takata
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Seki
authors.forename: Rie
authors.initials: R
authors.lastname: Imamura
authors.forename: Koichi
authors.initials: K
authors.lastname: Osaki
authors.forename: Michitoshi
authors.initials: M
authors.lastname: Hashiguchi
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Yakushiji
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Mouri
authors.forename: Shinichi
authors.initials: S
authors.lastname: Mizuno
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshimoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.forename: Koji
authors.initials: K
authors.lastname: Nagafuji
authors.forename: Takashi
authors.initials: T
authors.lastname: Okamura
mesh_terms: D000208:Acute Disease; D000328:Adult; D036101:Cord Blood Stem Cell Transplantation; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000628:therapy; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous; D061349:Unrelated Donors